IL6 and COVID-19: Another advantage of using CAR-NK cell-based therapy is that NK cells produce minimal proinflammatory cytokine IL-6, which has been shown to significantly contribute to the cytokine release syndrome (CRS) that is caused by CAR-T immunotherapy or observed in severe COVID-19 patients (33, 34).